Catalyst PharmaceuticalCPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Employees: 167
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
98% more call options, than puts
Call options by funds: $490K | Put options by funds: $248K
71% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 35
53% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 91
8% more capital invested
Capital invested by funds: $1.9B [Q3] → $2.06B (+$156M) [Q4]
7% more funds holding
Funds holding: 312 [Q3] → 333 (+21) [Q4]
1.27% more ownership
Funds ownership: 80.62% [Q3] → 81.89% (+1.27%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Baird Joel Beatty 50% 1-year accuracy 20 / 40 met price target | 27%upside $32 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 33% 1-year accuracy 118 / 356 met price target | 39%upside $35 | Buy Reiterated | 28 Feb 2025 |
Stephens & Co. Sudan Loganathan 22% 1-year accuracy 6 / 27 met price target | 31%upside $33 | Overweight Reiterated | 27 Feb 2025 |
B of A Securities Jason Gerberry 52% 1-year accuracy 11 / 21 met price target | 19%upside $30 | Buy Reiterated | 9 Jan 2025 |
Financial journalist opinion
Based on 12 articles about CPRX published over the past 30 days









